Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. - Wikidata - wikimedia - TriplyDB

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.

http://www.wikidata.org/entity/Q34804520

about

Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies Targeted cytolysins synergistically potentiate cytoplasmic delivery of gelonin immunotoxin.Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.Antiviral activity of a single-domain antibody immunotoxin binding to glycoprotein D of herpes simplex virus 2.Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P.Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu Targeting malignant B cells with an immunotoxin against ROR1 Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins.Immunogenicity of therapeutic recombinant immunotoxins.Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.Linked-in: design and efficacy of antibody drug conjugates in oncology Immunotoxins: the role of the toxin.Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growth.Hairy cell leukemia: short review, today's recommendations and outlook.Immunotoxins for leukemia.Recent advances in the application of antibodies as therapeutics.Dual targeting strategies with bispecific antibodies.Using antibodies to target cancer therapeutics.Designing immunoconjugates for cancer therapy.Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.Design and engineering of deimmunized biotherapeutics.Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems Immunotoxins in cancer therapy: Review and update.Efficient in vivo antitumor effect of an immunotoxin based on ribotoxin α-sarcin in nude mice bearing human colorectal cancer xenografts.2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA.Immunity to CRISPR Cas9 and Cas12a therapeutics.Computationally-driven identification of antibody epitopes.Development of a strategy and computational application to select candidate protein analogues with reduced HLA binding and immunogenicity.A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.Anti-ROR1 scFv-EndoG as a Novel Anti-Cancer Therapeutic Drug

P2860

Q27680195-39E25CE9-05D4-4C79-97F4-9026A1A1BA5B Q33647683-C9660BD2-C3A8-40A7-964B-8B4348C65E60 Q33652098-46A2062C-5144-4D14-AF5D-A3E6A3F994A7 Q33767727-24EE6534-50CB-42D2-BACA-9A44AA3AB965 Q33932779-77E4B247-4B63-4A02-BBEC-2A2886895796 Q34276680-E83CD12A-6542-41BB-96F2-ABA13575C628 Q34323838-28030A6B-15A9-4A92-B3B6-FF903EC50E5B Q34923432-3C79F5EB-991A-4FBA-9A2D-82D11718CE86 Q35018336-94EA548B-70B4-42E8-90E9-65E861C94D71 Q35070412-7C1B1CA4-3814-4AAA-BE15-3C04DBF632D2 Q35230663-895EEAD2-3866-4E47-928C-52BC56C35ADD Q35446035-0BF0E549-FB50-4B75-A562-6FFACDD4F45F Q35541200-3244B4BD-8DE1-43B1-B695-012D2A908FBD Q35969887-D85F1D65-FCB6-40D7-8189-051646793B65 Q35992503-285F1A10-028A-436E-9D0A-14E45499C5B5 Q36536466-2A6CEADE-56A2-405E-85B6-FE22E98A94B2 Q36544460-1F0BB074-1B48-430C-A9FD-8E684F9C427B Q36593468-83CCF74C-FC8E-46CC-A8E2-8478F5823E4C Q36917916-10E422F4-8946-444A-A0A7-8F5ADD525264 Q37029370-1925FDBC-A3C1-4421-A114-CE7DBB00E7E1 Q37139525-FE6E7815-6E4B-40C1-A4E4-8172850B9236 Q37327375-D2E8C698-669D-45A0-93FF-268203E07FC3 Q37577621-CEEAD2D5-BCB6-4A9C-94A0-5AB778A42802 Q37621357-28B1F02C-A694-4527-8118-5B812C1DA38E Q37709336-7E094867-B13D-45A5-A608-35D23AF292A1 Q37968255-128C6A12-1FC8-4ECC-B543-C46B2797DF11 Q37997559-F1CEC155-50EB-46A4-AA27-3837F444A8C3 Q38014920-FF354E52-D35A-4A0F-814C-E61710DF1052 Q38017203-5740F96A-BED9-4CE3-B8A6-A2E8BECB63C3 Q38094099-84E0BD50-BA97-4704-ABC3-16F509208041 Q38870681-74A51F98-1803-474E-B279-2E3E20627710 Q38885212-B6AF0427-4272-4D23-A052-35EDF751D70D Q39172843-69427B68-A63B-4F4C-A9A3-5C28F1ED6799 Q39516903-BA802E74-8133-4EF5-B3C8-F2E88C17EB45 Q42333514-D5EBCF35-21F7-4EF9-BF03-D1BB68C7C894 Q45873745-854A97F6-600A-4CE3-8F75-DAD4DA679FBD Q47098066-0B8277A1-B1B3-4D64-BB74-D9539068B797 Q47716213-A6EA10BC-F024-4B1F-84AC-4253AEFED5C1 Q48274415-EC3B6494-ABBB-4285-96AF-365A2E1B52F5 Q49648716-10BEA78D-4985-4A6E-B823-8AE545EDB5D2

P2860

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.

http://www.wikidata.org/entity/Q34804520

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Recombinant immunotoxin agains ...... by removal of B-cell epitopes.

@ast

Recombinant immunotoxin agains ...... by removal of B-cell epitopes.

@en

Recombinant immunotoxin agains ...... by removal of B-cell epitopes.

@nl

type

label

Recombinant immunotoxin agains ...... by removal of B-cell epitopes.

@ast

Recombinant immunotoxin agains ...... by removal of B-cell epitopes.

@en

Recombinant immunotoxin agains ...... by removal of B-cell epitopes.

@nl

prefLabel

Recombinant immunotoxin agains ...... by removal of B-cell epitopes.

@ast

Recombinant immunotoxin agains ...... by removal of B-cell epitopes.

@en

Recombinant immunotoxin agains ...... by removal of B-cell epitopes.

@nl

P1433

Q34804520-4704FF8C-B4EB-464B-B07F-72C6BF93BDDA

P1476

Q34804520-D2A4DD32-5BE3-4295-ACEB-61A49F0EAD49

P2093

Q34804520-389186C9-3402-4271-AC94-BB0740581403

Q34804520-5BFB2D0F-D5CB-4E8F-AA3F-E855283148FB

Q34804520-89EAD1B6-4BDC-41C0-B1A6-AF1F0804764D

Q34804520-90535C29-F97E-46ED-A296-0317E78E98F1

Q34804520-D8008D48-B04A-4043-950D-8510588A254C

Q34804520-E31B2847-E113-4472-9ECD-C8F2D8C96F39

P2860

Q34804520-006804E5-3F90-47F6-8D1F-33C9C00F7D13

Q34804520-030788E8-F070-4408-ABB3-EAEA07B43FE0

Q34804520-102798ED-8A46-49E1-A134-809051625382

Q34804520-13387B52-C23E-4A9C-BC78-A61FFAD9E2AC

Q34804520-33C921F1-3B94-4039-A963-3E62BBF25054

Q34804520-42D39A34-510F-48B6-996B-44AD58DBDBFA

Q34804520-43BCC645-A144-4584-9DAE-3691D76A038E

Q34804520-5AC2351B-782C-473C-A379-1128F74D5B55

Q34804520-5D455948-08DD-4475-BC53-EC8B8838E874

Q34804520-679493C4-8C7A-47ED-A873-16A18C7E19A1

P304

Q34804520-8F79454E-6643-4978-825C-CD917E2805C7

P31

Q34804520-8BCA23FE-73D1-4091-B160-9807BDBC9E82

P356

Q34804520-9D35EAF2-82C6-4439-9DE9-015CA04CBC79

P407

Q34804520-13F5BEB8-7410-418D-A63B-306862E6639D

P433

Q34804520-E6039031-2FEA-47F5-8DB2-F8C3AD7A4AA6

P478

Q34804520-E95B0539-2B79-40CE-A5C3-D80426B7D0E1

P50

Q34804520-9FB12C6E-83D4-4F37-B669-3E1083D05C13

P577

Q34804520-3624BDC4-3EF7-477B-8647-449BFAF9F41F

P5875

Q34804520-AE12AE7A-7789-41C1-9B01-237835D4DB0B

P698

Q34804520-D2E51D16-433C-41D3-9E22-7C5C69C72859

P932

Q34804520-77CD297B-9BF2-4BEE-B894-777F4F9DBFD4

P356

PNAS.1102746108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Recombinant immunotoxin agains ...... by removal of B-cell epitopes

@en

P2093

Byungkook Lee

http://www.w3.org/2001/XMLSchema#string

Ira Pastan

http://www.w3.org/2001/XMLSchema#string

Laiman Xiang

http://www.w3.org/2001/XMLSchema#string

Masanori Onda

http://www.w3.org/2001/XMLSchema#string

Richard Beers

http://www.w3.org/2001/XMLSchema#string

Robert J Kreitman

http://www.w3.org/2001/XMLSchema#string

P2860

Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction.

Minimizing the immunogenicity of protein therapeutics.

Immunogenicity of engineered antibodies.

An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.

Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.

P304

5742-5747

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1102746108

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50850468

http://www.w3.org/2001/XMLSchema#string

P698

21436054

http://www.w3.org/2001/XMLSchema#string

P932

3078343

http://www.w3.org/2001/XMLSchema#string